PD-1 and PD-1 ligands: from discovery to clinical application.

By Taku Okazaki, Tasuku Honjo. International Immunology, 2007

1,254 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/49bde0e800b46f1536a7a056e29f40d33e7933a2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells (2018, background): “Immuno-oncology has revolutionized cancer treatment (Okazaki and Honjo, 2007; Okazaki et al., 2013; Baumeister et al., 2016; Schumacher and Schreiber, 2015; Sharma and Allison, 2015a, 2015b).”
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 (2019, background): “PD-1, also known as CD279, belongs to CD28 superfamily [11].”
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma (2013, neutral): “M1a 1 (2) 3 (19) 6 (25) 3 (9) 1 (5) 14 (10)”
PD-1 and its ligands in tolerance and immunity. (2008, background): “A role for PD-1:PD-L in humans is suggested by polymorphisms in PDCD1 that have been associated with human autoimmune diseases, including systemic lupus erythematosus (SLE), type 1 diabetes, rheumatoid arthritis, Grave’s disease, and MS (76).”
Non-small cell lung cancer: current treatment and future advances. (2016, background): “Ultimately, the blocking of this pathway augments the T cell response in the body (85,86).”
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors (2010, background): “In addition, tumors themselves sometimes express PD-L1, which can negatively signal T cells through both the PD-1 and B7-1 molecules on their surface (5).”
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (2012, neutral): “All squamous type All doses 13 1 8 (0-36) ND 3 23 (5-54) 43 (15-71)”